Premium
Prognostic utility and clinical significance of lysyl oxidase‐like 2 protein expression in digestive system cancers
Author(s) -
Zhang Yi,
Liu Wanwei,
Xu Jiwei
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28677
Subject(s) - lysyl oxidase , hazard ratio , biomarker , oncology , medicine , confidence interval , metastasis , meta analysis , overall survival , stage (stratigraphy) , cancer research , bioinformatics , cancer , biology , enzyme , paleontology , biochemistry
Lysyl oxidase‐like 2 (LOXL2) participates in the occurrence and development of digestive system cancers (DSCs). The aim of this study was to determine whether LOXL2 protein could serve as a prognostic biomarker in patients with DSCs. Relevant studies published before October 1, 2018 were identified from a comprehensive literature review in PubMed, Web of Science, and Embase. This meta‐analysis was conducted via STATA/SE 14.1 software. Finally, a total of 12 publications and 6 different kinds of DSCs were identified. Meta‐analysis indicated that increased expression of LOXL2 protein was significantly correlated with reduced overall survival (hazard ratios [HR]: 1.52; 95% confidence interval [CI]: 1.32–1.72) and worse progression‐free survival/disease‐free survival (HR: 2.15; 95% CI: 1.48–2.83) in cases with DSCs. In addition, clinicopathological parameters, including tumor invasion, lymph node metastasis, distant metastasis, and clinical stage were significantly related to LOXL2 protein expression in DSCs. High LOXL2 protein expression is significantly associated with worse clinical outcomes in DSCs and its expression level may represent a candidate prognostic biomarker in these cancers.